PanWell-DSR is an advanced dual-action gastrointestinal medication specifically formulated for effective management of acid-peptic disorders. It combines 40 mg of Pantoprazole Sodium, a potent Proton Pump Inhibitor (PPI), with 30 mg of Domperidone, a reliable prokinetic agent, in a unique Multi-Particulate Delivery System. This combination ensures rapid and sustained relief from acid reflux, heartburn, nausea, and bloating through superior gastric pH control and improved motility. Its Pellet-in-Capsule technology features enteric-coated Pantoprazole pellets that release medication only in the small intestine, protecting the drug from stomach acidity and guaranteeing optimal absorption. The Domperidone sustained-release pellets provide controlled 24-hour action, preventing the common fluctuations associated with immediate-release formulas. PanWell-DSR is ideal for treating GERD, erosive esophagitis, peptic and duodenal ulcers, NSAID-induced gastritis, dyspepsia, and related gastrointestinal conditions. Its once-daily dosing and comprehensive symptom control make it a preferred choice for pharmaceutical suppliers and healthcare institutions seeking proven, high-quality acid-peptic disorder solutions.
Key Features
| Features | Description |
|---|---|
| Dual-Action Formula | Combines 40 mg Pantoprazole (PPI) with 30 mg Domperidone (Prokinetic) |
| Multi-Particulate Delivery System | Pellet-in-Capsule technology for enhanced bioavailability |
| Pantoprazole Pellet Coating | Enteric-coated pellets release drug in small intestine to avoid degradation in stomach |
| Domperidone Release Profile | Sustained release for 24-hour prokinetic and anti-emetic effects |
| Therapeutic Uses | Effective for GERD, peptic ulcers, dyspepsia, and NSAID-induced gastritis |
| Dosing | Once daily for sustained symptom control |
| Symptoms Controlled | Acidity, heartburn, nausea, bloating, vomiting, flatulence |
| Target Patient Profile | Patients with acid-peptic disorders requiring dual therapy |
| Manufacturing Compliance | Formulated with IP grade ingredients adhering to pharmaceutical quality standards |
| Attributes | Description |
|---|---|
| Pantoprazole Sodium IP | 40 mg per capsule (gastro-resistant pellets) |
| Domperidone IP | 30 mg per capsule (prolonged-release pellets) |
| Dosage Form | Pellet-in-Capsule |
| Delivery System | Multi-Particulate Delivery System (MPDS) |
| Indications | GERD, erosive esophagitis, peptic and duodenal ulcers, NSAID-induced gastritis, dyspepsia |
| Release Mechanism | Enteric coating for Pantoprazole; Sustained release for Domperidone |
| Recommended Dosage | Once daily oral administration |
| Shelf Life | As per packaging (typically 24 months) |
| Packaging | Available in bottles or blister strips as per customer requirement |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The MPDS pellet-in-capsule technology allows Pantoprazole pellets to resist stomach acid and release only in the small intestine, improving absorption, while Domperidone pellets provide sustained release to maintain steady prokinetic activity over 24 hours. This ensures continuous symptom relief and better therapeutic outcomes.
PanWell-DSR combines a Proton Pump Inhibitor and a Prokinetic agent, offering dual action that not only reduces gastric acid secretion but also improves gastric motility. This comprehensive approach addresses both acidity and delayed gastric emptying, providing faster and more effective relief than single-agent treatments.
Yes, PanWell-DSR is indicated for NSAID-induced gastritis as it protects the gastric mucosa by reducing acid secretion and promoting healing, thereby minimizing gastrointestinal side effects common in patients on prolonged NSAID use.
PanWell-DSR is designed for once-daily oral administration, providing 24-hour symptom control through its sustained-release formulation, enhancing patient compliance.
Yes, PanWell-DSR improves gastric motility and reduces bloating and fullness, making it effective for managing symptoms of functional dyspepsia in addition to acid suppression.
Brand: panwell-dsr
Country Of Origin: India
PanWell-DSR is a high-performance, dual-action gastrointestinal medication designed for the effective management of acid-peptic disorders. By combining a potent Proton Pump Inhibitor (PPI) with a reliable prokinetic agent, PanWell-DSR offers comprehensive relief from acidity, heartburn, and associated nausea.
Therapeutic Composition
Uses:
Main Therapeutic Uses of PanWell-DSR
Inclusive of all taxes
You Save: 0
Mumbai , India
Service Provider , Manufacturer, Brand Owner, Distributor, Exporter, Wholesaler
GST- 27bnopa9689r2zo
